LabCompass

Sumithira Vasu

Medicine · The Ohio State University

Mid career · publishing since 2008Rising activity

Publications

109

Citations

1,475

Est. group size

~13

Recurring co-author estimate

Active years

19

Publishing since 2008

Research summary
AI-generated

Sumithira Vasu's research centers on blood cancers and cellular therapies, including CAR-T cell treatments for leukemia, stem cell transplantation, and targeted drug therapies for rare blood cancers like blastic plasmacytoid dendritic cell neoplasm (BPDCN). Much of the work involves clinical trial data and real-world outcomes analysis for patients receiving these advanced treatments, including toxicity, survival, and relapse outcomes. This research is clinically oriented, often involving multi-institutional collaborations and consortiums studying treatment outcomes in adult leukemia patients.

CAR-T cell therapy for leukemiaStem cell/bone marrow transplantation outcomesBlastic plasmacytoid dendritic cell neoplasm treatmentAcute myeloid and lymphoblastic leukemia therapiesGraft-versus-host disease management

Publication output was relatively steady over the past decade with a notable surge in 2025, suggesting an increase in recent research and clinical trial activity.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026

Publication cadence
Publications per year over the last 10 years — averaging 8.8/year recently
2017: 2 publications172018: 8 publications182019: 5 publications192020: 8 publications202021: 8 publications212022: 5 publications222023: 4 publications232024: 5 publications242025: 29 publications29252026: 1 publication26
Recent publications
Publishes in
  • Blood×25
  • Transplantation and Cellular Therapy×12
  • Blood Advances×5
  • Journal of Clinical Oncology×4
  • Haematologica×4
Similar researchers
By research-topic overlap

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 19, 2026.

Claim or correct this profile